We use HER2 tyrosine kinase inhibitors (TKI) and HER2-amplified metastatic breast cancer to demonstrate that our approach can help deconvolute whether variability in response depends on tumor-intrinsic features, like growth rate and HER2+ fraction, or drug-specific properties, like PK and biodistribution. This evidence concerns the gene ERBB2 and breast cancer.